HFB1002 / HiFiBiO - LARVOL DELTA

CXCR5 as a Therapeutic Target in Autoimmune Diseases: Insights from Sjögren'sSyndrome (CIS 2025) - "Notably, HFB100204 selectively depletes CXCR5+ B cells more potently than rituximab and ianalumab from human PBMCs. This study underscores the therapeutic potential of targeting the CXCR5/CXCL13 axis for I&I. Using SS as an example, we show that at a single-cell level, CXCR5 is critical for the disease progression. HFB100204 effectively depletes pathogenic CXCR5+ immune cells, including B cells and Tfh cells, offering a novel strategy for autoimmune diseases."

Immunology • Inflammation • Inflammatory Arthritis • Sjogren's Syndrome • CXCL13 • CXCR5